CRNX250117P55000
- 4.13
- 0.000.00%
Crinetics Newsroom
Oppenheimer Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $81
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $55 to $92
Express News | Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals' Atumelnant Trial Data Prompts Hold Rating Amid Efficacy and Safety Concerns
Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment
Strong Buy Rating for Crinetics Pharmaceuticals Driven by Promising Atumelnant Data and Market Potential
Crinetics Pharmaceuticals Down Nearly 9%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2
Express News | Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals Strengthens Leadership With New Appointment
Crinetics Pharmaceuticals Analyst Ratings
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Express News | Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Press Release: Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $87